What do systematic reviews say?

Dexrazoxane vs no cardioprotective intervention

Dexrazoxane may leads to higher secondary malignant neoplasms Available‐case analysis compared with no cardioprotective intervention (low certainty).

• Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
  RR 3.08 [1.13, 8.38]
  3 studies · 1015 participants
  Low